bluebird bio, Inc. (NASDAQ:BLUE) Receives $4.63 Consensus PT from Analysts

bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) has earned an average recommendation of "Hold" from the twelve research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $4.63.

A number of equities research analysts recently issued reports on the stock. Bank of America dropped their price objective on shares of bluebird bio from $4.00 to $3.00 and set a "buy" rating for the company in a report on Thursday, August 15th. Robert W. Baird reduced their price target on shares of bluebird bio from $7.00 to $6.00 and set an "outperform" rating on the stock in a research report on Thursday, August 15th. Barclays cut their price objective on bluebird bio from $8.00 to $4.00 and set an "overweight" rating for the company in a research report on Thursday, August 15th. StockNews.com assumed coverage on shares of bluebird bio in a research report on Friday. They issued a "sell" rating on the stock. Finally, Wells Fargo & Company dropped their price target on shares of bluebird bio from $3.00 to $2.00 and set an "equal weight" rating for the company in a research report on Wednesday, September 25th.

bluebird bio Price Performance

Shares of bluebird bio stock remained flat at $0.49 on Tuesday. The stock had a trading volume of 3,002,641 shares, compared to its average volume of 7,500,730. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. The stock's fifty day moving average is $0.54 and its 200-day moving average is $0.84. The stock has a market cap of $53.77 million, a PE ratio of -0.67 and a beta of 0.75. bluebird bio has a fifty-two week low of $0.45 and a fifty-two week high of $5.53.

bluebird bio (NASDAQ:BLUE - Get Free Report) last released its quarterly earnings data on Friday, September 13th. The biotechnology company reported ($0.36) earnings per share for the quarter. bluebird bio had a negative return on equity of 207.25% and a negative net margin of 567.29%. The company had revenue of $18.57 million for the quarter. Research analysts forecast that bluebird bio will post -1.42 EPS for the current year.

Hedge Funds Weigh In On bluebird bio

Several institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its position in shares of bluebird bio by 152.4% during the third quarter. SG Americas Securities LLC now owns 122,855 shares of the biotechnology company's stock worth $64,000 after buying an additional 74,185 shares in the last quarter. AQR Capital Management LLC grew its holdings in bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company's stock worth $1,223,000 after acquiring an additional 1,013,144 shares in the last quarter. Allegheny Financial Group LTD purchased a new stake in shares of bluebird bio in the 2nd quarter valued at approximately $25,000. Rhumbline Advisers raised its holdings in shares of bluebird bio by 25.4% in the 2nd quarter. Rhumbline Advisers now owns 292,436 shares of the biotechnology company's stock valued at $288,000 after purchasing an additional 59,219 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of bluebird bio by 19.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 685,757 shares of the biotechnology company's stock worth $675,000 after purchasing an additional 111,574 shares during the last quarter. Institutional investors and hedge funds own 87.43% of the company's stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.